Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postnatal Betamethasone for Respiratory Weaning in ELGANs
NCT07447739Phase 2Not yet recruiting
- Start
- Apr 2026
- Primary completion
- Mar 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of betamethasone in respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD) (2 arms). Primary endpoint: Rate of successful respiratory weaning. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
betamethasone
03
Conditions
respiratory distress syndrome (RDS)bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT07447739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07447739.